We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Perspective Therapeutics, Inc. (CATX)

NYSE American - Nasdaq Real Time Price. Currency in USD
Visitors trend2W10W9M
1.4700+0.0500 (+3.52%)
At close: 04:00PM EDT
1.4300 -0.04 (-2.72%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
Previous Close1.4200
Open1.4000
Bid1.4300 x 4000
Ask1.4600 x 3100
Day's Range1.2900 - 1.5000
52 Week Range0.2100 - 1.6000
Volume5,104,640
Avg. Volume3,855,216
Market Cap862.766M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-0.1400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CATX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Perspective Therapeutics, Inc.
    Analyst Report: Becton, Dickinson And Co.Headquartered in Franklin Lakes, New Jersey, BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Its operations consist of three worldwide business segments: BD Medical, BD Life Sciences, and BD Interventional.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Perspective Therapeutics to Participate at Upcoming April Investor Conferences

    SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April. Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled Radiopharmaceuticals: Energizing Disruption in Therapeutics, at the Goldman Sachs Third Annu

  • GuruFocus.com

    Perspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results

    Significant R&D Investments Lead to Increased Losses Despite Revenue Gains from Grants

  • GlobeNewswire

    Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

    SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023. “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha

  • The Wall Street Journal

    Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal

    AstraZeneca became the latest big pharma to buy a company focused on an emerging approach to fighting cancer known as radiopharmaceuticals. On Tuesday, the Anglo-Swedish pharmaceutical said it is buying Fusion Pharmaceuticals for up to $2.4 billion as part of a plan to accelerate the development of next-generation cancer treatments. With the deal, AstraZeneca joins Eli Lilly, Bristol-Myers Squibb and Novartis in working to develop therapies that can deliver radioactive isotopes directly to cancer cells.

  • GlobeNewswire

    Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma

    SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety and tolerability of Perspective’s targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb’s nivolumab in patients with histologically confi

  • GlobeNewswire

    Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024

    SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET. To register, click here. The event will feature presentations from the following members of the Company’s manag

  • GlobeNewswire

    Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility

    SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art manufacturing facility and associated equipment and systems for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. Previously operated by Lantheus Holdings, Inc. (

  • GlobeNewswire

    Perspective Therapeutics Announces $87.4 Million Private Placement

    SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has entered into an investment agreement with a select group of institutional accredited investors, to sell securities in a private placement for aggregate gross proceeds of approximately $87.4 million, before deducting placement a

  • GlobeNewswire

    Perspective Therapeutics to Participate at Upcoming Investor Conferences

    SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that management will participate at upcoming discussions and investor conferences in February and March, 2024. Fireside Chat with JonesResearch – February 28, virtualTime: 11 a.m. ETParticipant: Michael K. Schultz, Ph.D., Chief Science Offi

  • The Wall Street Journal

    These Drug Companies Are Going Nuclear to Fight Cancer

    Big pharma’s investments in nuclear medicine highlight how cancer treatment is shifting to targeted approaches.